By Lucy Parkinson, Director of Research, LSN
Corporate venture capital funds have been a key pillar of the life science investment community for some time, and at LSN we’ve seen these groups evolving on strategy to keep up with an increasingly competitive investor marketplace. While many pharma firms still use corporate VC as a strategic vehicle for filling pipelines, these firms are increasingly collaborative and keen to be seen as aligned with the interests of entrepreneurs and other investors, as well as those of their parent companies.
At RESI, a panel of 5 top corporate VCs from around the world will explain how their group makes strategic investments in early stage companies, and how a corporate VC relationship can help a startup company get ahead in development and strategic relationships.
Moderated by Rajeev Dadoo (Partner, SR One), the participants are:
- Elaine Jones (Vice President, Pfizer Venture Investments)
- Vijay Murthy (Principal, Johnson & Johnson JJDC)
- Vikram Sudarsan (Head of Cipla Technologies, Cipla New Ventures)
- Andreas Jurgeit (Investment Director, Merck Ventures)
Next Phase Newsletter 
Leave a comment